Abstract Background Targeted therapies are a standard of care for first-line treatment of Anaplastic lymphoma kinase (ALK)-rearranged non small cell lung cancer (NSCLC). Giving the rapid pace of drug discovery and development in this area. reporting of adverse effects of ALK inhibitors is crucial. Here. https://www.roomyroomers.shop/product-category/bench/